The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Editorial

Thursday, 13 September 2012
Cardiovascular disease prevention is one of the main challenges facing primary care today. In order to reduce the burden of disease, national guidelines recommend that asymptomatic patients who are at high risk of cardiovascular disease should be offered preventive medications. This article discusses cardiovascular disease risk assessment, communication of this risk to patients and attitudes of both general practitioners and patients to preventive medications.
Category: Editorial
Thursday, 13 September 2012
The benefit of treatment with HMG-CoA reductase inhibitors (statins) is unquestioned, with multiple studies over the last 20 years having shown that statins improve cardiovascular (CV) outcomes.1 Although all statins reduce low-density lipoprotein cholesterol (LDL-C), their potencies differ. The decreasing order of potency (per milligram) for LDL-C reduction is: rosuvastatin, atorvastatin, simvastatin and pravastatin.
Category: Editorial
Thursday, 13 September 2012
Prominent consequences of the Health and Social Care Act which has now passed into law will be the increased commissioning of cardiac services and changes in how they are delivered. This Act, although establishing an NHS Commissioning Board to provide commissioning guidance, intends to increase markedly GPs' power to commission services. Monitor, the non-departmental public body, will be developed into an economic regulator to oversee access and competition within the NHS
Category: Editorial
Tuesday, 14 August 2012
Anticoagulation in Practice (AiP) in its current form was established approximately six years ago and comprises healthcare professionals and patients interested in the area of anticoagulation. Healthcare professionals include GPs, practice nurses, pharmacists, healthcare scientists, haematologists, community nurses and anticoagu­lation specialist nurses. Previously a collective of special interest groups, there is now a real opportunity to develop the AiP Society into a more robust body, unifying the concerns of both healthcare professionals and patients into a single organisation. With the collective expertise of the AiP Society our aims are to Develop and produce guidance for anticoagulation practitioners and patients e.g. the new oral anticoagulants, translating trial evidence into real life situations Provide a central point of information for all things to do with anticoagulation management Develop high quality educational activities Support practitioner level research Provide opportunities to attend scientific conferences for patients and those working directly with patients Improve patient services and patient safety Be an effective voice for informing policy development at all levels Maintain the pre-eminence of the annual AiP conference which has grown since 2004, to become a major event in the calendar for all those with an interest in the practicalities of anticoagu­lation management. To ensure that the AiP Society represents all healthcare professionals and patients involved with anticoagulation management in the UK your input is essential. With your input the AiP Society can become an effective voice for all of us who are concerned with the provision of high quality anticoagulation management. Please do join us in being part of this exciting initiative. Nicky Fleming Chair, Anticoagulation in Practice (AiP) Society To have greater involvement with the AiP Society please contact Amy Partleton This email address is being protected from spambots. You need JavaScript enabled to view it.. Links AiP website currently under development ACE website http://www.anticoagulationeurope.org
Category: Editorial
Wednesday, 06 June 2012
Who should be treated with these new agents? When should patients be switched from warfarin or aspirin? Speakers: Dr Matthew Fay GP and National Clinical Lead for Atrial Fibrillation, Westcliffe Medical Centre, Shipley Dr Frances Akinwunmi Consultant Pharmacist (Anticoagulation), Imperial College Healthcare NHS Trust
Category: Editorial
Wednesday, 06 June 2012
The management of AF is one of the most rapidly evolving areas of primary care today. How will these changes alter management in the coming months? Speakers: Dr Frances Akinwunmi Consultant Pharmacist (Anticoagulation), Imperial College Healthcare NHS Trust Professor David Fitzmaurice Professor of Primary Care, University of Birmingham Dr Matthew Fay GP and National Clinical Lead for Atrial Fibrillation, Westcliffe Medical Centre, Shipley
Category: Editorial
Wednesday, 06 June 2012
Are they all the same? What are the risks? Speakers: Dr Frances Akinwunmi Consultant Pharmacist (Anticoagulation), Imperial College Healthcare NHS Trust Professor David Fitzmaurice Professor of Primary Care, University of Birmingham Dr Matthew Fay GP and National Clinical Lead for Atrial Fibrillation, Westcliffe Medical Centre, Shipley Dr Patrick Kesteven Consultant Haematologist, Freeman Hospital, Newcastle-upon-Tyne
Category: Editorial
Wednesday, 06 June 2012
What are the issues which need to be considered? What are the priorities? Are there pitfalls? Speaker: Alison Tennant Head of Service Improvement and Quality, Dudley Clinical Commissioning Group
Category: Editorial

Article search and filter